[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100219718":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":26,"responsibleParty":46,"collaborators":25,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":25,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":25,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":25,"overallStatus":28,"whyStopped":25,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Sacramento Pediatric Gastroenterology","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Oral Vancomycin","EXPERIMENTAL","Every participant with PSC or BA will received the same Arm of Oral Vancomycin",[13],"Drug: Oral Vancomycin",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Oral Vancomycin is given to PSC or BA participants",[9],[20],"ANI",[22],{"name":23,"affiliation":5,"role":24},"Yinka Davies, M.D.","PRINCIPAL_INVESTIGATOR",null,[27],{"facility":5,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","Sacramento","California","95841","United States","US",{"type":35,"coordinates":36},"Point",[37,38],-121.4944,38.58157,{"lat":38,"lon":37},[41,45],{"name":42,"role":43,"phone":44,"phoneExt":25,"email":25},"Yinka Davies, MD","CONTACT","916-332-1244",{"name":23,"role":24,"phone":25,"phoneExt":25,"email":25},{"type":47,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100219718","phase-1-treating-primary-sclerosing-cholangitis-and-biliary-atresia-with-vancomycin-100219718",false,"NCT02137668","Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin","The Human Gastrointestinal Tract Microbiota in the Setting of Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin","Inclusion Criteria:\n\n* Persons who have primary sclerosing cholangitis, biliary atresia, a chronic intestinal disorder or who are undergoing upper or lower endoscopy.\n* Persons who have primary sclerosing cholangitis or biliary atresia who are good candidates for vancomycin therapy.\n\nExclusion Criteria:\n\n* Patients that have taken antibiotics and\u002For immunomodulators within the last 3 months will be excluded as this will alter the original bacterial flora.\n* Females who are pregnant may not participate.",true,"ALL","2 Weeks","40 Years",{"count":60,"type":61},200,"ESTIMATED","INTERVENTIONAL",[64],"PHASE1","The purpose of this study is twofold. First, is to determine whether vancomycin is effective in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and if so, by what mechanism. Secondly, to characterize human intestinal microbial communities and their interactions with the host.",[67,68],"Primary Sclerosing Cholangitis","Biliary Atresia","2016-11-10",{"date":71,"type":61},"2016-11-15",{"date":73,"type":25},"2010-07",{"date":75,"type":61},"2028-07",{"name":5,"class":6},1]